Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

426 Features
Facts about Dementia

07 Feb 06

The symptoms of Alzheimer’s disease can be treated by a class of drugs known as cholinesterase inhibitors (ChEI’s), which increase the availability of acetylcholine in the brain by inhibiting the enzyme acetylcholinesterase (AChE).
Stephen Cull

Flower power & Oncology

03 Feb 06

The size of the cytotoxic market in the seven major pharmaceutical markets is estimated to be approximately $9.6 billion. Datamonitor expects it to reach a peak of $12.8 billion by 2009. However, mainly due to major patent expiries, it is expected to drop to $11.3 billion by 2014. Topoisomerase inhibitors represent a subgroup of the plant alkaloid class of cytotoxics. DNA topoisomerase II inhibitors are among the most efficacious drugs for the treatment of cancer although they are associated wi
LeadDiscovery

Replidyne marches on in the development of novel antibiotics for the treatment of drug-resistant skin infections

03 Feb 06

The market for antibacterials, valued at $24 billion in the seven major markets, faces significant revenue loss in the period 2005-2007 due to major patent expiries. In exception, considerable success has been met by those targeting drug resistant infections. This is highlighted by the rapid uptake of products focused on drug-resistant infections, such as Pfizer's Zyvox (linezolid). Here we highlight a promising early stage candidate being developed by Replidyne, REP8839
LeadDiscovery

OX40:OX40L interaction – evolving from a key component of autoimmunity to a possible target for cardiovascular disease

31 Jan 06

OX40 (CD134) is one of the newer tumor necrosis factor receptor (TNFR) family members. Expressed on CD4+ T-cells, its activation by OX40L, a type II membrane protein expressed on activated B-cells, dendritic cells and macrophages, plays an important T-cell co-stimulatory role. Today we highlight additional involvement in heart disease
LeadDiscovery

Supercomputers used to go from genome to lead in under a month

25 Jan 06

Genomics and proteomics comprise a fundamental area of bioinformatics however exploiting the wealth of information gained using such disciplines remains a rate limiting step in the drug discovery process. Today’s edition of DailyUpdates (Jan 25th 2005) describes ground breaking work that has allowed researchers to identify candidate therapeutics for the treatment of SARs virus infection in under a month using the virus genome as a starting point
LeadDiscovery

Ferriprox prevents heart failure deaths in thalassaemia

16 Jan 06

A new study shows the oral iron-chelator Ferriprox (deferiprone) prevents patients with thalassaemia experiencing heart complications and dying of heart failure. Patients with the condition require frequent blood transfusions with the unwanted effect of excess iron that can build up in organs and endocrine glands. Iron overload in the heart can produce fatal complications so effective treatment with iron chelation therapy to remove iron is vital. The finding that an oral treatment achieves bett
Olwen Glynn Owen - PharmiWeb Field Reporter

2006 –Near Term Expectations for Clinical Research

11 Jan 06

There is little mystery about what the next few years hold for the clinical research industry –it comes down to one word: speed. It is all about speed. The gauntlet has been thrown down and the companies that are able to demonstrate an effective and consistent approach to truncating the timeline of clinical trials will be very successful.
Brian S. Robinson

What Future?

11 Jan 06

Perhaps the greatest challenge facing global drug development is the scarcity of new clinical research professionals entering the industry, bringing refreshing energy and ideas to their work, but lacking practical experience. Those involved in recruiting CR staff will be aware of this shortage and that experienced employees are seeking greater career management/development and rapid progression.
Iain Jessup

The Rough Guide to Electronic Data Capture

11 Jan 06

Electronic Data Capture (EDC), three little words that can divide the clinical research community like few others. To some, EDC is a panacea for all the troubles and rising costs of the clinical development process, whilst to others it spells broken promises, and forms the butt of many less than flattering anecdotes.
Andrew Salomon

Charity = Free Job Postings!

11 Jan 06

Free Job Postings for UK Charity Organisations in the Healthcare Sector.
Mike Wood

Blog your Jobs

10 Jan 06

New Blog for Jobs
Mike Wood

Rapid testing vital in tackling Bird Flu

04 Jan 06

Dr Adam Meijer of the Netherlands-based European Influenza Surveillance Scheme (EISS)§ has highlighted the vital role rapid testing must play in combating the global threat of bird flu. Dr Meijer makes his observations in the January issue of Expert Review of Molecular Diagnostics.
Simon Boisseau

Exjade - first oral treatment for iron overload - will make life easier for patients needing regular blood transfusion

22 Dec 05

New data presented at the American Society of Hematology meeting in Atlanta this month suggest the problems associated with iron overload in frequently-transfused patients can now be managed simply with an oral treatment rather than continuous infusions of several hours duration.
Olwen Glynn Owen PharmiWeb Field Reporter

Glivec improves long-term survival prospects for chronic myeloid leukaemia patients

21 Dec 05

Most patients who develop chronic myeloid leukaemia (CML) can now expect to live more than 20 years from diagnosis if they are treated with the tyrosine kinase inhibitor (TKI) Glivec (imatinib) according to haematologists involved in the IRIS (International Randomized Interferon versus STI571) study. Before availability of current treatments, median survival from diagnosis was 3.5 years.
Olwen Glynn Owen - PharmiWeb Field Reporter

How to | pass personality tests

06 Dec 05

Personality tests are commonly at interviews to calculate your personality "Type". It is likely that you will be faced with one during your career.
Martin Gibbons

ABBOTT LAUNCHES NEW PRECISION XTRA™ PLUS TEST STRIP IN EUROPE

30 Nov 05

Abbott Diabetes Care today introduced the new Precision Xtra™ Plus (Optium™ Plus in some markets) Glucose Test Strip in Europe for use with the Precision™ Xceed (Optium Xceed™ in some markets) Advanced Diabetes Management System at the 41st Annual Meeting of the European Association for the Study of Diabetes in Athens, Greece. The new test strip offers results in just five seconds and requires a small blood sample of only 0.6 micro litre. The new Precision Xtra Plus test strip provides reliabl
Sebastian Stokes

Dronedarone, a new anti-arrhythmic drug in development, may fill unmet need in atrial fibrillation

30 Nov 05

Dronedarone, a new Class III multi-channel blocking anti-arrhythmic drug currently in Phase III development by Sanofi-Aventis for the prevention of atrial fibrillation (AF) and atrial flutter (AFL) may help fill the unmet need for a safe pharmacologic treatment that effectively controls atrial fibrillation, cardiologists said this month. Sanofi-Aventis presented new data on dronedarone at the American Heart Association’s (AHA) annual scientific sessions held in Dallas.
Olwen Glynn Owen - PharmiWeb Field Reporter

HIV doctors underestimate patients’ willingness to use injectables

30 Nov 05

Patients who could benefit from injectable therapies are a lot less needle-phobic than doctors assume, according to research conducted by pharmacist and behavioural scientist Professor Robert Horne. The “Open Mind” study presented at the 10th European AIDS Conference/EACS in Dublin showed over three quarters of patients would be willing to accept self-administered subcutaneous injectable therapy if offered.
Olwen Glynn Owen - PharmiWeb Field Reporter

How to | Enter the cyberspace recruitment market

22 Nov 05

Caution: Your CV is your personal data. My advice as a recruiter, with many years experience in the clinical research industry, would be to take care where you send your CV and make sure your data is treated with the respect it deserves! The important thing is to be selective.
Linda Eden-Ellis

Executive Jobs

11 Nov 05

Due to demand, we at PharmiWeb have added a new Executive Jobs Listing to our comprehensive careers section. All these jobs include packages of over ÂŁ100K (GBP) per year.
Mike Wood

Pharmaceutical Abbreviations

31 Oct 05

For those new to the industry, a quick round up of the common abbreviations and what they stand for might be useful....
Spencer Marsh

Would you like a chance to win ÂŁ25!

24 Oct 05

Complete our user survey and you could win a ÂŁ25 Amazon voucher!
Mike Wood

Diabetes

13 Oct 05

The prevalence of diabetes, in particular type 2 diabetes, is increasing worldwide. Type 2 diabetes increases with age, but recently has been affecting much younger individuals. In the UK, diabetes prevalence has doubled over the last 12-15 years, and is set to double again over a similar timeframe. The prevalence of diabetes in the UK is now, on average, 3.3%, though many patients are undiagnosed.
CSF Medical

PharmiWeb Solutions and Microsoft host unique seminar...and plan next one!

29 Sep 05

On Wednesday 22nd June, PharmiWeb Solutions and Microsoft brought together a senior group of sales and marketing professionals, to discuss how software and e-business based solutions can deliver competitive advantage for the pharmaceutical organisation.
Colin Williams

PharmaSALES WORLD 2005

23 Sep 05

Pharma Sales World 2005 will provide delegates with a unique opportunity to gain critical business information about how Europe’s leading pharma companies are addressing the challenge of improving sales force effectiveness. The conference will highlight the issues of accessibility, emerging customer bases, market changes in the next decade, sales force size and structure, targeting and segmentation, the new breed of representative, data acquisition, training and development, customer relationshi
Hannah Reading

Osteoporosis

23 Sep 05

Fractures resulting from osteoporosis are widely recognised as a major cause of morbidity and mortality in the elderly population. It has been estimated that approximately 310,000 osteoporotic fractures occur annually in the UK, with a consequent cost to the health service of ÂŁ1.7 billion.
CSF Medical

Exco Group- Win Small Business of the Year 2005

20 Sep 05

On Friday 16th September, before a glittering audience of local business Champions, Exco was awarded the highly acclaimed prize of Small Business of the Year 2005.
Sarah Eadon

U.S. and EU NME/NAS Submissions Hit Five-Year High in 2004

06 Sep 05

The pharmaceutical industry’s new molecular entity (NME) submissions to the U.S. FDA and new active substance (NAS) submissions to the European Medicines Evaluation Agency (EMEA) rose to five-year highs in 2004, according to PAREXEL’s Pharmaceutical R&D Statistical Sourcebook 2005/2006.
http://www.barnettinternational.com

Epilepsy

05 Sep 05

Epilepsy is characterised by a tendency to experience unprovoked seizures and is one of the most common neurological disorders. Over 2% of the population will experience a seizure at some time in their life, and recurrent unprovoked seizures will require treatment in approximately one-in-200 people at any given time. Treatment of epilepsy remains important in helping to reduce the psychological and social sequelae which follow on from uncontrolled seizures.
CSF Medical

Schizophrenia

22 Aug 05

It is often forgotten that until the late 1950s there was no treatment for schizophrenia, or for that matter, any other severe enduring mental illness. The majority of patients admitted to asylum care never left: hence the peak occupancy of 150,000 reported in the UK in 1955. As an interesting comparison, this is twice the current UK prison population.
CSF Medical

Advertising